Biomx INC 8-K filings

BiomX Inc. stockholders approved the election of three Class II directors, authorized a reverse stock split, and ratified their independent accounting firm at the 2025 Annual Meeting.

BiomX Inc. announced the FDA's clinical hold on its BX004 Phase 2b study for Cystic Fibrosis is now limited to nebulizer device questions, with no concerns about the drug product, and topline results remain expected in Q1 2026.

BiomX Inc. announced a clinical hold by the FDA on its Phase 2b study for BX004 in Cystic Fibrosis due to a third-party nebulizer review, pausing U.S. enrollment while European operations continue.

BiomX announced positive Phase 2 results for BX211 in diabetic foot osteomyelitis and commenced Phase 2b dosing for BX004 in Cystic Fibrosis, alongside its second quarter 2025 financial results.

BiomX Inc. has announced the date for its 2025 Annual Meeting of Stockholders as October 16, 2025, and set the deadline for shareholder proposals for inclusion in its proxy statement.

BiomX Inc. announced the publication of new efficacy data from its Phase 1b/2a trial of BX004 in Nature Communications, demonstrating significant bacterial reduction and a strong safety profile for cystic fibrosis patients with chronic Pseudomonas aeruginosa infections.

BiomX Inc. announced positive Phase 2 clinical trial results for its lead phage therapy candidates, BX211 and BX004, demonstrating significant efficacy against antibiotic-resistant bacterial infections in diabetic foot osteomyelitis and cystic fibrosis patients, respectively.

BiomX reports positive Phase 2 trial results for BX211 in diabetic foot osteomyelitis and anticipates Phase 2b results for BX004 in cystic fibrosis in Q1 2026.

BiomX Inc. stockholders approved the exercise of certain warrants and a proposal for adjournment at a special meeting held on April 21, 2025.

BiomX reports successful Phase 2 trial results for BX211, a phage therapy targeting Diabetic Foot Osteomyelitis, showing statistically significant ulcer reduction and safety.

BiomX reports financial results for Q4 and full year 2024, providing updates on BX211 and BX004 clinical programs and recent financing.

BiomX Inc. announces the closing of a $12 million offering, including a registered direct offering, a concurrent private placement, and the exercise of existing warrants.

BiomX secures $12 million in funding through a registered direct offering, concurrent private placement, and warrant exercise to support its Phase 2b study of BX004 for cystic fibrosis.

BiomX Inc. announced it has regained compliance with NYSE American listing standards after resolving prior deficiencies.

BiomX reports completion of patient enrollment for its BX211 DFO trial and a delay in the BX004 CF trial results, alongside its Q3 2024 financial results.

BiomX Inc. will mandatorily separate its units into common stock and warrants, with the units ceasing trading on October 25, 2024, while the common stock will continue to trade under the symbol PHGE.

BiomX Inc. presented an investor update on September 26, 2024, detailing progress in their phage therapy programs targeting chronic infections.

BiomX Inc. will implement a 1-for-10 reverse stock split of its common stock and units, effective August 26, 2024.

BiomX has been granted an extension until November 23, 2025, to regain compliance with NYSE American listing standards.

BiomX Inc. stockholders approved an amended incentive plan and an increase in authorized common stock shares at their annual meeting on July 9, 2024.

BiomX Inc. has finalized its acquisition of Adaptive Phage Therapeutics, adding two Phase 2 assets to its pipeline and expanding its focus on phage-based therapies.

BiomX Inc. has received a notice from the NYSE American for failing to meet continued listing standards due to a stockholders equity deficiency, requiring the company to submit a compliance plan by June 22, 2024.

BiomX Inc. has increased its board size to eight members, appointed a new director, and amended its bylaws to remove the requirement for an odd number of directors.

BiomX acquired Adaptive Phage Therapeutics, secured $50 million in funding, and is advancing its clinical-stage phage therapy programs for cystic fibrosis and diabetic foot osteomyelitis.

BiomX Inc. has finalized committee assignments for its recently appointed directors, effective immediately.

BiomX Inc. finalized its acquisition of Adaptive Phage Therapeutics, issuing warrants to a landlord and appointing new board members, while also filing a Certificate of Designation for Series X preferred stock.

BiomX Inc. is set to acquire Adaptive Phage Therapeutics, enhancing its phage therapy pipeline and securing $50 million in private financing.